Folate-mediated intracellular drug delivery increases the anticancer efficacy of nanoparticulate formulation of arsenic trioxide

Molecular Cancer Therapeutics

Volumn 8, Issue 7, 2009, Pages 1955-1963

  Chen, Haimei ^a   Ahn, Richard ^a   Van Den Bossche, Jeroen ^b   Thompson, David H ^b   O'Halloran, Thomas V ^a  

^a NORTHWESTERN UNIVERSITY   (United States)

^b PURDUE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARSENIC TRIOXIDE; FOLATE RECEPTOR; FOLIC ACID; LIPOSOME; NANOPARTICLE;

ARTICLE; CANCER CELL CULTURE; CONFOCAL MICROSCOPY; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG DELIVERY SYSTEM; DRUG UPTAKE; ENDOCYTOSIS; HUMAN; HUMAN CELL; MASS SPECTROMETRY; PRIORITY JOURNAL;

ANTINEOPLASTIC AGENTS; ARSENICALS; BREAST NEOPLASMS; DRUG CARRIERS; DRUG DELIVERY SYSTEMS; FEMALE; FLOW CYTOMETRY; FOLIC ACID; HUMANS; LIPOSOMES; NANOPARTICLES; NASOPHARYNGEAL NEOPLASMS; OXIDES; TUMOR CELLS, CULTURED;

EID: 67651183769     PISSN: 15357163     EISSN: None     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-09-0045     Document Type: Article

References (45)

1. Zhu J, Chen Z, Lallemand-Breitenbach V, de The H. How acute promyelocytic leukaemia revived arsenic. Nat Rev Cancer 2002;2:705-13.
2. Wang ZY, Chen Z. Acute promyelocytic leukemia: from highly fatal to highly curable. Blood 2008;111:2505-15.
3. Berenson JR, Yeh HS. Arsenic compounds in the treatment of multiple myeloma: a new role for a historical remedy. Clin Lymphoma Myeloma 2006;7:192-8.
4. Dilda PJ, Hogg PJ. Arsenical-based cancer drugs. Cancer Treat Rev 2007;33:542-64.
5. 3) in the orthotopic metastasis model of androgen-independent prostate cancer. Cancer Res 2001;61:5432-40.
6. Kito M, Matsumoto K, Wada N, et al. Antitumor effect of arsenic trioxide in murine xenograft model. Cancer Sci 2003;94:1010-4.
7. Chen Z, Chen GQ, Shen ZX, et al. Expanding the use of arsenic trioxide: leukemias and beyond. Semin Hematol 2002;39:22-6.
8. Liu B, Pan S, Dong X, et al. Opposing effects of arsenic trioxide on hepatocellular carcinomas in mice. Cancer Sci 2006;97:675-81.
9. Evens AM, Tallman MS, Gartenhaus RB. The potential of arsenic trioxide in the treatment of malignant disease: past, present, and future. Leuk Res 2004;28:891-900.
10. Ni J, Chen G, Shen Z, et al. Pharmacokinetics of intravenous arsenic trioxide in the treatment of acute promyelocytic leukemia. Chin Med J (Engl) 1998;111:1107-10.
11. Wang Z, Zhou J, Lu X, Gong Z, Le XC. Arsenic speciation in urine from acute promyelocytic leukemia patients undergoing arsenic trioxide treatment. Chem Res Toxicol 2004;17:95-103.
12. Allen TM, Cullis PR. Drug delivery systems: entering the mainstream. Science 2004;303:1818-22.
13. Li SD, Huang L. Pharmacokinetics and biodistribution of nanoparticles. Mol Pharm 2008;5:496-504.
14. Gabizon AA. Pegylated liposomal doxorubicin: metamorphosis of an old drug into a new form of chemotherapy. Cancer Invest 2001;19: 424-36.
15. Kallinteri P, Fatouros D, Klepetsanis P, Antimisiaris SG. Arsenic trioxide liposomes: encapsulation efficiency and in vitro stability. J Liposome Res 2004;14:27-38.
16. Yang Z, Yang M, Peng J. Evaluation of arsenic trioxide-loaded albumin nanoparticles as carriers: preparation and antitumor efficacy. Drug Dev Ind Pharm 2008;34:834-9.
17. Ni Dhubhghaill OM, Sadler PJ. The structure and reactivity of arsenic compounds: biological activity and drug design. Struct Bonding (Berlin) 1991;78:129-90.
18. Chen H, MacDonald RC, Li S, Krett NL, Rosen ST, O'Halloran TV. Lipid encapsulation of arsenic trioxide attenuates cytotoxicity and allows for controlled anticancer drug release. J Am Chem Soc 2006;128:13348-9.
19. Mellman I, Fuchs R, Helenius A. Acidification of the endocytic and exocytic pathways. Annu Rev Biochem 1986;55:663-700.
20. Steinman RM, Mellman IS, Muller WA, Cohn ZA. Endocytosis and the recycling of plasma membrane. J Cell Biol 1983;96:1-27.
21. Sudimack J, Lee RJ. Targeted drug delivery via the folate receptor. Adv Drug Deliv Rev 2000;41:147-62.
22. Low PS, Henne WA, Doorneweerd DD. Discovery and development of folic-acid-based receptor targeting for imaging and therapy of cancer and inflammatory diseases. Acc Chem Res 2008;41:120-9.
23. Gabizon A, Horowitz AT, Goren D, et al. Targeting folate receptor with folate linked to extremities of poly(ethylene glycol)-grafted liposomes: in vitro studies. Bioconjug Chem 1999;10:289-98.
24. Haran G, Cohen R, Bar LK, Barenholz Y. Transmembrane ammonium sulfate gradients in liposomes produce efficient and stable entrapment of amphipathic weak bases. Biochim Biophys Acta 1993;1151:201-15.
25. Rettig WJ, Cordon-Cardo C, Koulos JP, Lewis JL, Jr., Oettgen HF, Old LJ. Cell surface antigens of human trophoblast and choriocarcinoma defined by monoclonal antibodies. Int J Cancer 1985;35:469-75.
26. Garin-Chesa P, Campbell I, Saigo PE, Lewis JL, Jr., Old LJ, Rettig WJ. Trophoblast and ovarian cancer antigen LK26. Sensitivity and specificity in immunopathology and molecular identification as a folate-binding protein. Am J Pathol 1993;142:557-67.
27. Donaldson M, Antignani A, Milner J, et al. p47phox-deficient immune microenvironment signals dysregulate naive T-cell apoptosis. Cell Death Differ 2009;16:125-38.
28. Sonvico F, Dubernet C, Marsaud V, et al. Establishment of an in vitro model expressing the folate receptor for the investigation of targeted delivery systems. J Drug Deliv Sci Technol 2005;15:407-10.
29. Lu Y, Low PS. Immunotherapy of folate receptor-expressing tumors: review of recent advances and future prospects. J Control Release 2003; 91:17-29.
30. Saul JM, Annapragada A, Natarajan JV, Bellamkonda RV. Controlled targeting of liposomal doxorubicin via the folate receptor in vitro. J Control Release 2003;92:49-67.
31. Gerasimov OV, Boomer JA, Qualls MM, Thompson DH. Cytosolic drug delivery using pH- and light-sensitive liposomes. Adv Drug Deliv Rev 1999;38:317-38.
32. Bahlis NJ, McCafferty-Grad J, Jordan-McMurry I, et al. Feasibility and correlates of arsenic trioxide combined with ascorbic acid-mediated depletion of intracellular glutathione for the treatment of relapsed/refractory multiple myeloma. Clin Cancer Res 2002;8:3658-68.
33. Lallemand-Breitenbach V, Guillemin M-C, Janin A, et al. Retinoic acid and arsenic synergize to eradicate leukemic cells in a mouse model of acute promyelocytic leukemia. J Exp Med 1999;189:1043-52.
34. Gartenhaus RB, Prachand SN, Paniaqua M, Li Y, Gordon LI. Arsenic trioxide cytotoxicity in steroid and chemotherapy-resistant myeloma cell lines: enhancement of apoptosis by manipulation of cellular redox state. Clin Cancer Res 2002;8:566-72.
35. Baumgartner M, Sturlan S, Roth E, Wessner B, Bachleitner-Hofmann T. Enhancement of arsenic trioxide-mediated apoptosis using docosahexaenoic acid in arsenic trioxide-resistant solid tumor cells. Int J Cancer 2004;112:707-12.
36. Sturlan S, Baumgartner M, Roth E, Bachleitner-Hofmann T. Docosahexaenoic acid enhances arsenic trioxide-mediated apoptosis in arsenic trioxide-resistant HL-60 cells. Blood 2003;101:4990-7.
37. Dai J, Weinberg RS, Waxman S, Jing Y. Malignant cells can be sensitized to undergo growth inhibition and apoptosis by arsenic trioxide through modulation of the glutathione redox system. Blood 1999;93: 268-77.
38. Yang CH, Kuo ML, Chen JC, Chen YC. Arsenic trioxide sensitivity is associated with low level of glutathione in cancer cells. Br J Cancer 1999; 81:796-9.
39. Rao MV, Parekh SS, Chawla SL. Vitamin-E supplementation ameliorates chromium- and/or nickel induced oxidative stress in vivo. J Health Sci 2006;52:142-7.
40. Hansen JM, Zhang H, Jones DP. Differential oxidation of thioredoxin-1, thioredoxin-2, and glutathione by metal ions. Free Radic Biol Med 2006; 40:138-45.
41. Pari L, Prasath A. Efficacy of caffeic acid in preventing nickel induced oxidative damage in liver of rats. Chem Biol Interact 2008;173:77-83.
42. Sasame HA, Boyd MR. Paradoxical effects of cobaltous chloride and salts of other divalent metals on tissue levels of reduced glutathione and microsomal mixed-function oxidase components. J Pharmacol Exp Ther 1978;205:718-24.
43. Yildirim O, Buyukbingol Z. Effect of cobalt on the oxidative status in heart and aorta of streptozotocin-induced diabetic rats. Cell Biochem Funct 2003;21:27-33.
44. Dalvi RR, Robbins TJ. Comparative studies on the effect of cadmium, cobalt, lead, and selenium on hepaticmicrosomal monooxygenase enzymes and glutathione levels in mice. J Environ Pathol Toxicol 1978;1:601-7.
45. Shmeeda H, Mak L, Tzemach D, Astrahan P, Tarshish M, Gabizon A. Intracellular uptake and intracavitary targeting of folate-conjugated liposomes in a mouse lymphoma model with up-regulated folate receptors. Mol Cancer Ther 2006;5:818-24.